The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
The partnership initially will focus on cardiovascular and kidney diseases
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Subscribe To Our Newsletter & Stay Updated
